0.81
+0.0224(+2.86%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.8 |
| Day High | 0.81 |
| Day Low | 0.78 |
| 52-Week High | 2.75 |
| 52-Week Low | 0.73 |
| Volume | 49,349 |
| Average Volume | 291,717 |
| Market Cap | 6M |
| PE | -0.4 |
| EPS | -2 |
| Moving Average 50 Days | 1.21 |
| Moving Average 200 Days | 1.56 |
| Change | 0.02 |
If you invested $1000 in Intelligent Bio Solutions Inc. (INBS) since IPO date, it would be worth $0.3 as of November 12, 2025 at a share price of $0.807. Whereas If you bought $1000 worth of Intelligent Bio Solutions Inc. (INBS) shares 3 years ago, it would be worth $7.89 as of November 12, 2025 at a share price of $0.807.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year
GlobeNewswire Inc.
Nov 04, 2025 1:30 PM GMT
Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and Reader Revenue Up Approximatel
Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of 33 new
Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider
GlobeNewswire Inc.
Oct 23, 2025 12:30 PM GMT
Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer account highlights accelerating adoption of the Company's rapid, non-invasive drug testing technology across hig